Clinical Trials Browser

OTHER_GOV × Pathologic Complete Response × Docetaxel × Clear all

NCT06927180 2025-06-23

SHR-A1811 Plus Pertuzumab in the Neoadjuvant Treatment of HER2 Positive BC

Phase 2 Recruiting

Pathologic Complete Response, Breast Neoplasms

NCT05474690 2024-02-26

A Study Comparing the Efficacy of TCbHP and ECHP-THP in the Neoadjuvant Treatment of HER2-positive Breast Cancer

Phase 3 Withdrawn

Pathologic Complete Response, Breast Neoplasms